WariActiv Vapo Coolant Anesthesia Aerosol Spray, Ethyl Chloride 의 안전성 경고

Food and Drug Administration Philippines에 따르면, 해당 안전성 경고 는 Philippines 에서 N/A 에 의해 제조된 제품과 관련되어 있습니다.

이것은 무엇인가요?

안전성 경고는 의료기기 제품과 관련된 중요한 정보와 권고사항을 담고 있습니다. 물론 안전성 경고가 배포되었다고 해서 해당 제품이 무조건 안전하지 않은 제품이라는 것은 아닙니다. 보건의료업계 종사자와 의료기기 사용자들에게 배포되는 안전성 경고에는 회수(recall)도 포함될 수 있습니다. 제조사가 안전성 경고를 작성하기도 하지만, 보건당국에서 작성하는 경우도 있습니다.

데이터에 대해 더 자세히 알아보기 여기
  • 사례 유형
    Safety alert
  • 사례 연번
    2017-086
  • 사례 국가
  • 사례 출처
    FDAP
  • 사례 출처 URL
  • 비고 / 경고
    Data from the Philippines is current through 2019. All of the data comes from the Food and Drug Administration Philippines, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Philippines.
  • 데이터 추가 비고
  • 원인
    Fda advisory no. 2017-086 public health warning against misuse of wariactiv® vapo coolant anesthesia aerosol spray, ethyl chloride the food and drug administration (fda) advises the public against the misuse of wariactiv® vapo coolant anesthesia aerosol spray, ethyl chloride (please see picture below). the said product is a registered medical device and was approved as local skin anesthesia. however, the fda received reports that the product is being indiscriminately used by some individuals. the product is being misused by inhaling it to feel “high” or happy. the abuse and misuse of the product’s active ingredient, ethyl chloride, could lead to the following adverse effects: acute (short-term) inhalation exposure to high levels of ethyl chloride in humans has resulted in temporary feelings of drunkenness, dizziness, lack of muscle coordination and unconsciousness.* chronic (long-term) effects include ataxia (uncoordinated movements), tremors, speech difficulties, slowed reflexes, involuntary eye movement, and hallucinations, and liver effects were reported in individuals who purposely inhaled very high concentrations of ethyl chloride for a few months.* sudden sniffing death syndrome**                                                               in the interest of protecting public health and safety from adverse health effects brought about by the abuse and misuse of the product, the public is hereby advised to use the product only in accordance with its approved use. likewise, advertisement of the product in all forms of media other than its approved use is prohibited. retailers are also advised to avoid indiscriminate selling of the product to customers. for more information and inquiries, please email us at this email address is being protected from spambots. you need javascript enabled to view it. or call the product research and standards development division of the fda - center for device regulation, radiation health and research at 857-1900 local 8301. dissemination of the information to all concerned is requested. references: 1. united states environmental protection agency website*                          (https://www.Epa.Gov/sites/production/files/2016-09/documents/ethyl-chloride.Pdf)                   2. dr. lynn crisanta r. panganiban, professor, department of pharmacology & toxicology, up college of medicine/consultant, national poison management & control center, up college of medicine – philippine general hospital** attachments: fda advisory no. 2017-086.Pdf.

Device

  • 모델명 / 제조번호(시리얼번호)
  • Manufacturer
    N/A

Manufacturer

N/A
  • Source
    FDAP